ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

References

Kavanagh J, Jackson DJ, Kent BD. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019 Mar;15(1):e20-e27. doi: 10.1183/20734735.0362-2018. PMID: 31031841; PMCID: PMC6481983.
Yaghoubi M, Adibi A, Zafari Z, FitzGerald JM, Aaron SD, Johnson KM, Sadatsafavi M. Cost-effectiveness of implementing objective diagnostic verification of asthma in the United States. J Allergy Clin Immunol. 2020 May;145(5):1367-1377.e4. doi: 10.1016/j.jaci.2019.11.038. Epub 2019 Dec 11. PMID: 31837372.
von Bülow A, Backer V, Bodtger U, Søes-Petersen NU, Vest S, Steffensen I, Porsbjerg C. Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol. Respir Med. 2018 Dec;145:41-47. doi: 10.1016/j.rmed.2018.10.020. Epub 2018 Oct 22. PMID: 30509715.
Zhang Q, Wu WW, Li L, McDonald VM, Chen YC, Wang G, Gibson PG. Workup of difficult-to-treat asthma: implications from treatable traits. Precis Clin Med. 2023 Feb 24;6(1):pbad003. doi: 10.1093/pcmedi/pbad003. PMID: 36968614; PMCID: PMC10037422.
Vanessa M. McDonald, James Fingleton, Alvar Agusti, Sarah A. Hiles, Vanessa L. Clark, Anne E. Holland, Guy B. Marks, Philip P. Bardin, Richard Beasley, Ian D. Pavord, Peter A.B. Wark, Peter G. Gibson on behalf of the participants of the Treatable Traits Down Under International Workshop. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019 May 9;53(5):1802058. doi: 10.1183/13993003.02058-2018. PMID: 30846468.
Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659-668. doi: 10.1016/S0140-6736(17)31281-3. Epub 2017 Jul 4. PMID: 28687413.
Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. Chest. 2024 Sep 6:S0012-3692(24)05139-0. doi: 10.1016/j.chest.2024.08.045. Epub ahead of print. PMID: 39245321.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Erratum in: Lancet. 2024 Mar 23;403(10432):1140. doi: 10.1016/S0140-6736(24)00544-0. PMID: 38071986.
Soendergaard MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, Hilberg O, Hansen S, von Bulow A, Porsbjerg C. Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study). Eur Respir J. 2024 Aug 22;64(2):2400404. doi: 10.1183/13993003.00404-2024. PMID: 38843910; PMCID: PMC11339407.

References

#{title}